Navigation Links
Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
Date:4/29/2009

ise sufficient funds for development or working capital; that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; and that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients. and. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including its Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; its annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by Forms 10-K/A filed with the SEC on December 23, 2008 and April 20, 2009; and its Form 10-Q filed with the SEC on April 13, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons -acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. Raptor expressly disclaims any intent or obligation t
'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014   Santa Clara dentist , Dr. ... for Invisalign. Invisalign is an orthodontic system that uses ... often the orthodontic treatment of choice for older teens ... it. For a limited time, patients can try Invisalign ... the usual cost. This offer cannot be combined, and ...
(Date:9/2/2014)... 2014 -- ... het ESC CONGRESS 2014 geven inzicht in ... op beroerte in de dagelijkse klinische praktijk ... 12.500 patiënten ingeschreven in de Global Anticoagulant ... innovatief, onafhankelijk initiatief op het gebied van ...
(Date:9/2/2014)... , September 2, 2014 ... Column Market by Type (Empty, Pre-packed, Analytical, Preparative), by Material (Metal, ... Chromatography, UFLC), TLC,SFC] - Forecast to 2018", published by MarketsandMarkets, ... in 2013. It is poised to grow at a ... by 2018. Browse 90 market data ...
Breaking Medicine Technology:Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... Mylan Inc. (Nasdaq: MYL ) today announced ... from the U.S. Food and Drug Administration (FDA) for ... Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg. , ... Bristol Myers Squibb,s Parkinson,s treatment Sinemet®, 10mg/100mg, 25mg/100mg and ...
... JERUSALEM, Israel, September 30 Gamida Cell ... generic,name of what is widely known as "StemEx", as ... The article, carlecortemcel-l, an ex vivo expanded,umbilical cord blood ... Chan and Dr. Demetrios Petropoulos, will be published in ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... Tulsa, OK (PRWEB) September 03, 2014 ... in the sales, installation, and support of Sage 100 ... named a Sage North America Million Dollar Club achiever ... 2013-2014 business year. Sage recognizes CS3 Technology and all ... to the overall success of Sage, its business partners ...
(Date:9/3/2014)... Gorda, FL (PRWEB) September 03, 2014 ... healthcare delivery, increases patient safety, decreases medical errors, ... providers. , To mark the important role ... in America, IHS and others across the U.S. ... Technology (NHIT) Week , September 16-20, 2014. With ...
(Date:9/3/2014)... September 03, 2014 Immersion Active ... received a silver medal in the 2014 Content Marketing ... Marketing Awards is the leading awards program for people ... of every medium and strategic purpose. , Immersion ... developed for its client Home Instead Senior Care®. This ...
(Date:9/3/2014)... OR (PRWEB) September 03, 2014 ... the use of appropriate evidence-based health care along ... parties benefit from the expertise of accredited independent ... the health care system. , As a core ... IROs often settle questions of medical necessity. Yet ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:CS3 Technology Named a Sage Million Dollar Club Achiever for 2013-2014 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Immersion Active Wins Silver for Email Strategy in 2014 Content Marketing Awards 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3
... Healthcare practitioners can increase the number of patients with heart ... cent, helping them to reduce their risk of dying and ... Munk Cardiac Centre. Previous studies, including one by ... a cardiac illness, such as a heart attack, can reduce ...
... Randy Dotinga HealthDay Reporter , MONDAY, Feb. ... Bull, AMP and Rockstar have no health value and ... review finds. The increasingly popular, highly caffeinated drinks ... hyperactivity disorder (ADHD) or other health or emotional problems, ...
... MONDAY, Feb. 14 (HealthDay News) -- Most medical devices recently ... life-threatening or serious safety risks were initially approved for use ... research reveals. The findings call out for an overhaul ... the market in the first place, said the study team, ...
... have a subtype that is characterized by high levels ... tends to be more aggressive than other breast cancer ... is so aggressive could aid in the development of ... researchers, led by Lewis Chodosh, at the University of ...
... , MONDAY, Feb. 14 (HealthDay News) -- ... Afghanistan and Iraq and who were evacuated due to ... military personnel to return to duty, new research shows. ... Department of Defense civilians -- account for about 50 ...
... / MEDai, a leading provider of advanced clinical analytic ... version of Pinpoint Review, its real-time, clinical surveillance system ... set of clinical watch triggers, expanded core measure alerts ... Stay Prediction and Mortality Prediction. "Hospitals are ...
Cached Medicine News:Health News:Heart patients should be referred to Cardiac Rehabilitation before leaving hospital 2Health News:Heart patients should be referred to Cardiac Rehabilitation before leaving hospital 3Health News:Energy Drinks May Hurt Kids: Study 2Health News:Energy Drinks May Hurt Kids: Study 3Health News:Report Blames Speedy FDA Clearance for Medical Device Recalls 2Health News:Report Blames Speedy FDA Clearance for Medical Device Recalls 3Health News:Nonmilitary More Likely to Return to War Zone After Psych Condition 2Health News:Elsevier/MEDai enhances real-time clinical surveillance system for hospitals 2
... Foot Control allows hands-free operation in nerve ... or 5.0 mA) with SoloStim provides a ... fine control when close to nerve., ... nerve block products, including the clinically proven ...
... ,The Centiva/5 Critical Care Ventilator is your solution ... critical care environment. The Centiva has been designed ... size with high levels of performance. The Centivas ... patients bed and allows you the freedom to ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
Medicine Products: